The Week in Review: Jinhe Biotech Stages $79 Million IPO in Shenzhen

Jinhe Biotechnology of Inner Mongolia raised $78.6 million in an IPO on the Shenzhen’s SME Exchange; Tianjin Joint Academy of Biotechnology and Medicine (TJAB) formed a JV with Australia’s Antisense Therapeutics to develop ANP’s multiple sclerosis drug; Lee’s Pharma of Hong Kong bought China rights to a novel clinical-stage peptide from RegeneRx Biopharma; Chengdu Hoist is selling its veterinary biological business; the Wuhan Institute of Biological Products (WIBF) formed a vaccine collaboration with Refine Technology of the US; China Health Resource announced a new TCM migraine medication built around Dahurian Angelica; Shanghai Jia Fu Medical Apparatus completed the dosing of two patients with a stem cell treatment developed by MediStem of the US; and Ironwood Pharma filed to start a China Phase III trial of linaclotide in patients with irritable bowel syndrome. More details…. Stock Symbols: (SHE: 002688) (ASX: ANP) (HK: 950) (OTCBB: RGRX) (SHE: 000790) (OTCBB: CHRI) (PinkSheets: MEDS) (NSDQ: IRWD) Share this with colleagues: var switchTo5x=true; stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'});